Regional committees for medical and health research ethics
Project owner/ Project manager
Norwegian Institute of Public Health
Participant at FHI
Clinical trials of drugs have restrictions that limit the knowledge of new drugs at the time of marketing: relatively few people in a limited period of time have been exposed to the drug. Signs of adverse reactions should therefore be evaluated after the drugs have been taken in normal use by the population using epidemiological studies in which systematic bias is attempted to be avoided. Knowledge of how drugs are used in the population is also important. The project will provide information on how medicines are used in the general population - and on effects and side effects - by linking the Norwegian Prescription Database with the Cause of Death Register, the Patient Register, the Cancer Registry, health surveys (three counties, 40-year surveys 1985-1999 and CONOR 1994-2003) and socioeconomic information from Statistics Norway. The following specific issues are included:
a) Use of the insulin analogue Lantus and cancer risk.
b) Medicine use and diagnoses for ADHD.
c) Use of psychiatric drugs among children and adolescents.
d) Medical prevention of stroke in atrial fibrillation.
e) Drug treatment before and after hospital admissions for asthma.
f) The connection between the use of sedative medicine, sleep medicine, cancer and mortality.
g) Prescription drug use among cancer survivors.
h) Prescription of drugs for and mortality of cardiovascular disease
i) Sleep problems, hypnosis and later ADHD.
See the full project description at Cristin for more information about results, researchers, contact information etc.
Svetlana Skurtveit, Avdeling for psykiske lidelser, Norwegian Institute of Public Health
Øystein Karlstad, Avdeling for kroniske sykdommer og aldring, Norwegian Institute of Public Health
Marte Handal, Avdeling for psykiske lidelser, Norwegian Institute of Public Health
Rune Kvåle, Avdeling for helseregisterforskning og -utvikling, Norwegian Institute of Public Health
Tone Bjørge, Institutt for global helse og samfunnsmedisin, University of Bergen
Kari Furu, Avdeling for kroniske sykdommer og aldring, Norwegian Institute of Public Health
Per Magnus, Senter for fruktbarhet og helse, Norwegian Institute of Public Health
Magne Thoresen, Department of Biostatistics, University of Oslo
Eva Skovlund, Department of Public Health and Nursing, Norwegian University of Science and Technology
Inger Johanne Bakken, Senter for fruktbarhet og helse, Norwegian Institute of Public Health
Jens Christoffer Skogen, Avdeling for helsefremmende arbeid, Norwegian Institute of Public Health
Anders Engeland, Avdeling for kroniske sykdommer og aldring, Norwegian Institute of Public Health
Børge Sivertsen, Avdeling for helsefremmende arbeid, Norwegian Institute of Public Health
Sara Ghaderi, Institutt for global helse og samfunnsmedisin, University of Bergen
Ingeborg Hartz, Avd Forskning, Innlandet Hospital Trust
Randi Marie Selmer, Avdeling for kroniske sykdommer og aldring, Norwegian Institute of Public Health
Morten Andersen, Karolinska Institute
Paul Peeters, Utrecht University
Lars Jøran Kjerpeseth, Division of Internal Medicine, University Hospital of North Norway
Ingvild Holdø, Universitetet i Oslo, University of Oslo
Peter Vestergaard, Aalborg University
Jon Marius Grasto Wickmann, Avdeling for helseundersøkelser, Norwegian Institute of Public Health
Heleen K Bronsveld, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
Jari Haukka, University of Helsinki
Helena Niemi Eide, Avdeling for smitte fra mat, vann og dyr, Norwegian Institute of Public Health
Marloes T. Bazelier, Utrecht University
Mark C.H. De Groot, Utrecht University
Anna But, University of Helsinki
Jacob S. Linde, Aarhus University Hospital
Marjaka K. Schmidt, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
Matti Siivola, University of Helsinki
Nils Ekstrøm, Karolinska Institute
Stine A. Eriksen, Aalborg University
Yared Santa Ana Tellez, Utrecht University
Zoltan Thinsz, Karolinska Institute